📈 Economy
Miss
✦ AI
The US labor market has been resilient throughout 2026: June added 172,000 jobs (vs 85,000 consensus), unemployment at 4.3%. The 80,000 threshold is well below the six-month trend. Risks: energy sector layoffs at lower WTI prices (this platform predicts WTI >$80/bbl on July 22 — moderate oil prices), Iran conflict dampening capital investment. Even a significant labor market slowdown is unlikely to breach 80,000. No specific Polymarket market for July 2026 NFP available.
📈 Economy
Miss
✦ AI
VW faces Chinese EV price pressure (BYD, Geely), structural restructuring costs (plant closures announced 2025/26), 25% US tariffs on EU cars and weak European car demand. Adjusted EBIT in H1 2025 was already ~22% below prior year. Consensus forecasts for 2026 anticipate further EBIT pressure. No Polymarket market; estimate based on structural headwinds.
📈 Economy
Hit
✦ AI
Airbnb reports Q2 2026 on August 6 after market close. EPS consensus: $1.19 (+15.5% YoY); revenue consensus: $3.58B (+15.7% YoY). Elevated oil prices (Brent ~$88-90) tend to shift travellers toward short-trip and domestic stays, where Airbnb excels. Airbnb beat EPS consensus in 5 of the last 6 quarters. No Polymarket market found.
📈 Economy
Miss
✦ AI
Volkswagen Group ended FY2025 after its massive restructuring program (German plant closures, EUR 10bn savings target) with adjusted EBIT margin of ~4.0–4.3%. H1 2026 remains under continued pressure: China sales collapse via BYD/SAIC cannibalization (VW market share China fell to ~12%), US tariffs (25%) weigh on Audi and Porsche imports, BEV segment remains unprofitable despite ID.7 Pro/Buzz ramp-up. VW communicated internal targets of >5% EBIT margin by 2028 — implying below-par performance in 2026 is expected. No Polymarket contract for this event.
📈 Economy
Hit
✦ AI
Novo Nordisk reports H1-2026 results on August 5 at 07:30 CEST. EPS consensus is $5.31; revenue consensus ~DKK 73.06B (Unusual Whales/MarketBeat, July 2026). Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 1.0/2.0 mg) dominate the globally growing GLP-1 market. Novo has beaten EPS consensus in more than six consecutive quarters. Risks: US IRA negotiations on GLP-1 reimbursement, competition from Eli Lilly's tirzepatide, China price pressure. No specific prediction market.
📈 Economy
Miss
✦ AI
Eli Lilly reports on August 5, 2026. The EPS consensus per Hudson Labs is ~$8.89 adjusted Non-GAAP EPS. Eli Lilly has beaten estimates for eight consecutive quarters, driven by explosive growth of Mounjaro (tirzepatide, diabetes/GLP-1) and Zepbound (obesity). The GLP-1 segment grows double-digits and routinely outpaces analyst estimates. No Polymarket market available; assessment based on ~85–90% historical beat rate over the last 8 quarters. Risk: potential supply constraints or price pressure from IRA negotiations.
📈 Economy
Miss
✦ AI
Uber guided Q2 2026 Non-GAAP EPS of $0.78–$0.82 per share. The analyst consensus at ~$0.84 is materially above the midpoint of Uber's own guidance – a recurring pattern that often leads to beats. Uber posted strong Q1 2026 results; Q2 Gross Bookings guidance is $56.25–57.75 billion. Key drivers: continued mobility growth in North America and Asia, plus Delivery expansion. Uber consistently beats when guiding conservatively. No Polymarket quote for Uber EPS; own estimate: ~65%.
📈 Economy
Hit
✦ AI
The ISM Services PMI for June 2026 came in at 54.0, matching consensus and firmly in expansion territory. The US services sector has been in uninterrupted expansion for 12+ months. Sub-indices: Business Activity 55.4%, New Orders 55.1%, Employment 51.2%. Even a sharp July pullback would be unlikely to breach the 50 threshold. No Polymarket anchor; historical Services PMI stability above 50 is well-established. Note: this is the Services PMI — the ISM Manufacturing PMI for July is already separately forecast.
📈 Economy
Hit
✦ AI
Disney+ and Hulu have been profitable since Q2 FY2025 and continue growing. The ESPN direct-to-consumer service (launched autumn 2025) expands the subscription portfolio. The Parks segment is recovering from earlier hurricane headwinds. The consensus of $1.88 per share (+16.8% YoY) looks conservative: Disney's historical beat rate over the last six quarters is approximately 80%. No Polymarket quote; calibrated on streaming momentum and operational improvement trends.
📈 Economy
Hit
✦ AI
Eli Lilly reports on August 5, 2026 before market open. The company is the global market leader in the GLP-1 segment (Mounjaro/Zepbound). Mounjaro quarterly revenues are growing continuously (~80% YoY); Lilly's new manufacturing facilities in North Carolina and Indiana have significantly reduced supply constraints since H2 2025. Lilly has beaten EPS consensus for five consecutive quarters and raised annual guidance four times. The Zepbound approval portfolio (obesity, heart failure) continues to expand. No Polymarket market; own estimate 79% based on structurally strong GLP-1 growth trajectory.
📈 Economy
Hit
✦ AI
ISM Services PMI data for July 2026 will be released on August 5. In June 2026 the index stood at 54.0, in May 2026 at 54.5 — keeping the US services sector solidly in expansion territory for months. The 53.0 threshold is significantly below recent readings; a drop below 53 would require an acceleration of the decline of more than 2 index points vs June. Headwinds from softening private consumption and elevated rates (currently 3.50–3.75%) are to be factored in, but insufficient to push below 53. No Polymarket/Kalshi price available; trend extrapolation based on 6-month baseline.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5. Consensus stands at $8.81–8.85 adjusted EPS per TipRanks. In Q1 2026, Lilly beat by a remarkable 24.8% ($8.55 vs. $6.85 expected), driven by strong tirzepatide (Mounjaro/Zepbound) volumes and sustained GLP-1 demand. Manufacturing capacity was massively expanded in 2025–2026. Risks: US healthcare pricing pressure, potential rebate negotiations. Beat probability: 76%, as consensus estimates after a large Q1 beat tend to lag full ramp-up.
📈 Economy
Hit
✦ AI
Novo Nordisk reports Q2 2026 on August 5. The ADS EPS consensus stands at approximately $0.82 per TipRanks. GLP-1 demand for semaglutide (Ozempic/Wegovy) remains structurally strong; Novo benefits from global capacity expansion and growing reimbursements in Europe and the US. Competitive pressure from Eli Lilly (tirzepatide) is priced in. Novo has beaten EPS consensus in each of the last four quarters. Beat probability: 71%. Currency risk (DKK/USD, EUR/USD) could dampen USD ADS translation. No Polymarket market available.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5 before market open. EPS consensus is approx. $8.89/share (Meyka/TipRanks); revenue consensus is $20.5B. Structural driver: GLP-1 demand for Mounjaro (diabetes) and Zepbound (obesity) remains relentless; Lilly is market leader in the fast-growing incretin segment. Lilly has consistently beaten estimates in recent quarters. Risk factors: incretin production capacity constraints; potential US drug pricing pressure (IRA implementation). No Polymarket odds found; beat probability structurally high.
📈 Economy
Miss
✦ AI
Turkish annual inflation peaked above 85% in October 2022 and has fallen sharply on orthodox monetary policy (rate hiking cycle from May 2023, policy rate >40%) — reaching approximately 44% by December 2024. The disinflation trend continued through 2025; analysts estimate Turkish inflation at 20–35% for mid-2026 depending on trajectory. Breaking below 25% for July 2026 hinges critically on wage growth dynamics, energy imports (Brent at USD 87 weighs on TRY-denominated import costs) and the exchange-rate path. Risk: the elevated oil price may slow disinflation and delay the sub-25% crossing to Q4 2026. No Polymarket signal available. Assessment: 40% probability — ambitious but achievable threshold within the ongoing disinflation cycle.
📈 Economy
Hit
✦ AI
Consensus: ~USD 1.34 Non-GAAP EPS (+396% YoY vs. Q2 2025: USD 0.27). AMD beat in 3 of the last 4 quarters, driven by strong AI GPU demand (MI300X/MI350 datacenter accelerators) and share gains vs. NVIDIA in high-performance computing. High-end analyst estimates reach USD 1.62 – well above consensus. The AI chip cycle remains intact in Q2 2026.
📈 Economy
Hit
✦ AI
AMD guided Q2 2026 revenue of $11.2B at ~56% non-GAAP gross margin—~46% YoY growth driven by strong MI300X AI accelerator demand. Street EPS consensus: $1.62. Goldman Sachs raised its price target to $640 (upgrade), Citigroup to $575 (upgraded to Buy). AMD's 'Advancing AI' event July 22–23, 2026 showcased new AI GPU products. No specific Polymarket market for AMD Q2 found; 70% probability based on guidance quality and analyst sentiment. Risk: HBM memory supply constraints or intensified Nvidia competition.
📈 Economy
Hit
✦ AI
BP reports Q2 2026 on August 4, 2026 (07:00 BST, live Q&A with CEO Meg O'Neill and CFO Kate Thomson). Brent crude was elevated in Q2 2026 (April–June) due to Middle East tensions, crossing $100/bbl by late July (+7% WoW). Under Meg O'Neill, BP has rationalized its cost base. The $2.0B threshold is below expected Q1 2026 levels and appears achievable in the current price environment. No Polymarket data; ~60% probability.
📈 Economy
Hit
✦ AI
Q2 2026 consensus EPS: USD 6.25 (+32.4% YoY vs. USD 4.72 in Q2 2025); revenue consensus USD 16.57 billion. Caterpillar benefits from global infrastructure spending (US IIJA, EU investment programs), sustained mining demand (copper, lithium), and pricing power. FY2026 EPS projection: USD 24.85 (+30.4% YoY). CAT has a strong historical beat rate in robust macro quarters; global construction machinery benefits from energy-transition investments. No Polymarket market; calibrated at 68% based on historical CAT beat rate, lightly discounted for macro uncertainty.
📈 Economy
Hit
✦ AI
Marriott reports Q2 2026 on August 4. Consensus is $3.05–3.06 EPS (+14–16% vs Q2 2025: $2.65). In Q1 2026, Marriott beat estimates by $0.16 (actual $2.72 vs. consensus $2.56 — +6.3% surprise). Three of the last four quarters produced EPS beats. Global hospitality remains robust: occupancy rates and RevPAR growth underpin the upper margin profile; leisure and business travel demand holds despite the economic cool-down. No Polymarket/Kalshi price available; own estimate based on beat rate, ESP metric, and demand trend.